Chemotherapy Effects - Pipeline Review, H2 2013

Description: Chemotherapy Effects - Pipeline Review, H2 2013

Summary

Global Markets Direct's, 'Chemotherapy Effects - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Effects, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Effects. Chemotherapy Effects - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Effects.
- A review of the Chemotherapy Effects products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Effects pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Effects.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Effects pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Chemotherapy Effects Overview
 Therapeutics Development
 An Overview of Pipeline Products for Chemotherapy Effects
 Chemotherapy Effects Therapeutics under Development by Companies
 Chemotherapy Effects Therapeutics under Investigation by Universities/Institutes
 Late Stage Products
 Comparative Analysis
 Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Chemotherapy Effects Therapeutics – Products under Development by Companies
Chemotherapy Effects Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Chemotherapy Effects Therapeutics Development
Adherex Technologies Inc.
Lentigen Corporation
Sigma-Tau S.p.A.
CEL-SCI Corporation
Hana Biosciences, Inc.
La Jolla Pharmaceutical Company
Telik, Inc.
LG Life Sciences, Ltd
Pluristem Therapeutics Inc.
BioAlliance Pharma SA
Spectrum Pharmaceuticals, Inc.
Helsinn Healthcare S.A.
Wellstat Therapeutics Corporation
Ventria Bioscience
PledPharma AB
Tranzyme Pharma, Inc.
ProCertus BioPharm Inc.
Indus Biotech Private Limited
Sound Pharmaceuticals, Inc.
SpePharm Holding B.V.
Neumedicines Inc.
Applied Protein Sciences, LLC
Chemotherapy Effects – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Sodium Thiosulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
menadione - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clonidine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leukocyte Interleukin Injection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TZP-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ezatiostat hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LG-631 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R&D Progress
Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-BMP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
calcitriol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLED-mangafodipir trisodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NecroX-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VEN-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Apoptosis Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MT-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OralX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chemotherapy Effects Therapeutics - Drug Profile Updates
Chemotherapy Effects Therapeutics - Discontinued Products
Chemotherapy Effects Therapeutics - Dormant Products
Chemotherapy Effects - Product Development Milestones
Featured News & Press Releases
May 28, 2013: Helsinn And Zealand Pharma Announce Decision To Advance Development Of Elsiglutide Into Phase Iib For Prevention Of Chemotherapy-induced Diarrhea
Feb 26, 2013: PledPharma Receives DSMB Approval To Continue Patient Recruitment In Phase II Study Of PledOx
Feb 14, 2013: BioAlliance Pharma Announces Forthcoming Extension Of Its Phase II Clinical Trial With Valdive In US
Feb 12, 2013: Recipharm Supplies Clinical Trial Material For FDA Approved Phase Iib Study Sponsored By PledPharma
Jan 30, 2013: Kissei Pharma Announces Filing Of New Drug Application For Dexrazoxane In Japan
Jan 22, 2013: New Drug Protects Against Side Effects Of Chemotherapy, Researchers Report
Jan 22, 2013: PledPharma Receives FDA Approval For Phase Iib Trial Of PledOx
Dec 27, 2012: PledPharma's PledOx Shows Superior Ability To Reduce Chemotherapy Side Effects, New Study Finds
List of Tables

Number of Products Under Development for Chemotherapy Effects, H2 2013
Products under Development for Chemotherapy Effects – Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2013

Adherex Technologies Inc., H2 2013
Lentigen Corporation, H2 2013
Sigma-Tau S.p.A., H2 2013
CEL-SCI Corporation, H2 2013
Hana Biosciences, Inc., H2 2013
La Jolla Pharmaceutical Company, H2 2013
Telik, Inc., H2 2013
LG Life Sciences, Ltd, H2 2013
Pluristem Therapeutics Inc., H2 2013
BioAlliance Pharma SA, H2 2013
Spectrum Pharmaceuticals, Inc., H2 2013
Helsinn Healthcare S.A., H2 2013
Wellstat Therapeutics Corporation, H2 2013
Ventria Bioscience, H2 2013
PledPharma AB, H2 2013
Tranzyme Pharma, Inc., H2 2013
ProCertus BioPharm Inc., H2 2013
Indus Biotech Private Limited, H2 2013
Sound Pharmaceuticals, Inc., H2 2013
SpePharm Holding B.V., H2 2013
Neumedicines Inc., H2 2013
Applied Protein Sciences, LLC, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Chemotherapy Effects Therapeutics – Drug Profile Updates
Chemotherapy Effects Therapeutics – Discontinued Products
Chemotherapy Effects Therapeutics – Dormant Products

List of Figures

Number of Products under Development for Chemotherapy Effects, H2 2013
Products under Development for Chemotherapy Effects – Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 50

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2615210/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Chemotherapy Effects - Pipeline Review, H2 2013
Web Address: http://www.researchandmarkets.com/reports/2615210/
Office Code: SCD2FP2I

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________________________
Job Title: _______________________________________
Organisation: _______________________________________
Address: _______________________________________
City: _______________________________________
Postal / Zip Code: _______________________________________
Country: _______________________________________
Phone Number: _______________________________________
Fax Number: _______________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World